lutetium vipivotide tetraxetan


( Last Updated : June 22, 2022)
Generic Name:
lutetium vipivotide tetraxetan
Project Status:
Pending
Therapeutic Area:
Metastatic castration-resistant prostate cancer
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0297-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Genitourinary
Indications:
The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.